Development of replication-competent viral vectors for HIV vaccine delivery.
Development of replication-competent viral vectors for HIV vaccine delivery.
复制标题
DOI：
10.1097/coh.0b013e328363d389
复制
发表时间：
2013-09
影响因子：
4.1
通讯作者：
King CR
中科院分区：
文献类型：
--
作者：
Parks CL;Picker LJ;King CR
简要描述一些正在研究的可复制（RC）载体，用于开发候选HIV疫苗，主要关注已在猕猴中进行测试或已进入临床试验的技术。RC病毒载体已经发展到可以就HIV疫苗的未来开发做出决定的阶段。用作RC载体平台的病毒差异很大，它们独特的属性使得可以测试多种疫苗设计概念，并模拟HIV感染的各个方面。编码SIV或HIV蛋白的RC病毒载体可用于安全地免疫猕猴，并且在某些情况下，在攻击保护研究中有显著疫苗功效的证据。几种活的HIV疫苗载体正在进行临床试验，以评估免疫原性、安全性、粘膜递送的效果和预先存在的免疫力的潜在影响。多种DNA和RNA病毒正被用于开发用于HIV疫苗递送的RC病毒载体。多种病毒载体平台已被证明是安全和免疫原性的，在猕猴中具有疗效的证据。一些基于水泡性口炎病毒、牛痘病毒、麻疹病毒和仙台病毒的更先进的HIV疫苗原型正在临床试验中。
Briefly describe some of the replication-competent (RC) vectors being investigated for development of candidate HIV vaccines focusing primarily on technologies that have advanced to testing in macaques or have entered clinical trials. RC viral vectors have advanced to the stage were decisions can be made regarding future development of HIV vaccines. The viruses being used as RC vector platforms vary considerably, and their unique attributes make it possible to test multiple vaccine design concepts and also mimic various aspects of an HIV infection. RC viral vectors encoding SIV or HIV proteins can be used to safely immunize macaques, and in some cases, there is evidence of significant vaccine efficacy in challenge protection studies. Several live HIV vaccine vectors are in clinical trials to evaluate immunogenicity, safety, the effect of mucosal delivery, and potential effects of pre-existing immunity. A variety of DNA and RNA viruses are being used to develop RC viral vectors for HIV vaccine delivery. Multiple viral vector platforms have proven to be safe and immunogenic with evidence of efficacy in macaques. Some of the more advanced HIV vaccine prototypes based on vesicular stomatitis virus, vaccinia virus, measles virus, and Sendai virus are in clinical trials.